Head and Neck Cancer Clinical Trial
Official title:
A Phase III Double-Blind, Randomised, Placebo-Controlled Study of Porfiromycin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. It is not yet known whether radiation therapy followed by porfiromycin is more
effective than radiation therapy alone in treating patients with head and neck cancer.
PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of
radiation therapy followed by porfiromycin in treating patients with stage III or stage IV
head and neck cancer.
OBJECTIVES: I. Determine the time to tumor progression in patients with stage III or IV
(without distant metastases) head and neck cancer treated with porfiromycin as adjuvant
therapy to radiotherapy. II. Determine percentage of patients with locoregional tumor
recurrence up to 2 years posttreatment. III. Determine response rate, disease free survival
time, and overall survival time in these patients. IV. Evaluate the safety and tolerance of
porfiromycin in these patients.
OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients
are stratified according to primary tumor site (oral vs pharynx vs larynx) and disease stage
(both T and N stage: T1-2 vs T3-4 and N0 vs N1-2 vs N3). All patients are randomized to
receive either porfiromycin (arm I) or placebo (arm II) as adjuvant therapy to radiation
therapy. Both arms follow the same treatment schedule. Daily radiation therapy commences on
day 1. Patients receive porfiromycin or placebo by intravenous infusion over 30-60 minutes
on day 5 and then on day 46 or 47. Porfiromycin or placebo is administered 30 minutes to 2
hours following radiation therapy. All patients with N3 neck disease (metastases in a lymph
node more than 6 cm in greatest dimension) undergo a planned neck dissection following
external beam radiation at 4 to 12 weeks following therapy. This surgery is not needed for
patients with N3 neck disease who do not have residual disease following radiotherapy.
Patients are followed at 4 weeks, then every 2 months for 2 years, and then every 6 months
for 3 years.
PROJECTED ACCRUAL: A total of 550-600 patients will be accrued for this study within 3
years.
;
Allocation: Randomized, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |